Literature DB >> 24704824

KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway.

H Li1, X Jiang2, Y Yu2, W Huang2, H Xing2, N Y Agar2, H W Yang2, B Yang3, R S Carroll2, M D Johnson4.   

Abstract

Aberrant splicing of the cyclin-dependent kinase-associated phosphatase, KAP, promotes glioblastoma invasion in a Cdc2-dependent manner. However, the mechanism by which this occurs is unknown. Here we show that miR-26a, which is often amplified in glioblastoma, promotes invasion in phosphatase and tensin homolog (PTEN)-competent and PTEN-deficient glioblastoma cells by directly downregulating KAP expression. Mechanistically, we find that KAP binds and activates ROCK2. Thus, RNA-mediated downregulation of KAP leads to decreased ROCK2 activity and this, in turn, increases Rac1-mediated invasion. In addition, the decrease in KAP expression activates the cyclin-dependent kinase, Cdk2, and this directly promotes invasion by increasing retinoblastoma phosphorylation, E2F-dependent Cdc2 expression and Cdc2-mediated inactivation of the actomyosin inhibitor, caldesmon. Importantly, glioblastoma cell invasion mediated by this pathway can be antagonized by Cdk2/Cdc2 inhibitors in vitro and in vivo. Thus, two distinct RNA-based mechanisms activate this novel KAP/ROCK2/Cdk2-dependent invasion pathway in glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24704824     DOI: 10.1038/onc.2014.49

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  The multifaceted mechanisms of malignant glioblastoma progression and clinical implications.

Authors:  Rui Sun; Albert H Kim
Journal:  Cancer Metastasis Rev       Date:  2022-08-03       Impact factor: 9.237

2.  A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis.

Authors:  Qinghuang Chen; Ke Chen; Guijie Guo; Fang Li; Chao Chen; Song Wang; Grzegorz Nalepa; Shile Huang; Ji-Long Chen
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

3.  Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma.

Authors:  Jia Wang; Tong Yang; Gaofeng Xu; Hao Liu; Chunying Ren; Wanfu Xie; Maode Wang
Journal:  Transl Oncol       Date:  2016-11-16       Impact factor: 4.243

Review 4.  Novel Insights into the Roles of Rho Kinase in Cancer.

Authors:  Lei Wei; Michelle Surma; Stephanie Shi; Nathan Lambert-Cheatham; Jianjian Shi
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-01-02       Impact factor: 4.291

5.  Overexpression of RASD1 inhibits glioma cell migration/invasion and inactivates the AKT/mTOR signaling pathway.

Authors:  Shangfeng Gao; Lei Jin; Guangping Liu; Peng Wang; Zonghan Sun; Yujia Cao; Hengliang Shi; Xuejiao Liu; Qiong Shi; Xiuping Zhou; Rutong Yu
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

6.  Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.

Authors:  Valeriana Cesarini; Maurizio Martini; Lucia Ricci Vitiani; Giovanni Luca Gravina; Silvia Di Agostino; Grazia Graziani; Quintino Giorgio D'Alessandris; Roberto Pallini; Luigi M Larocca; Pellegrino Rossi; Emmanuele A Jannini; Susanna Dolci
Journal:  Oncotarget       Date:  2017-02-21

Review 7.  Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?

Authors:  Christin Riess; Nina Irmscher; Inken Salewski; Daniel Strüder; Carl-Friedrich Classen; Christina Große-Thie; Christian Junghanss; Claudia Maletzki
Journal:  Cancer Metastasis Rev       Date:  2020-11-08       Impact factor: 9.264

8.  Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.

Authors:  Miao Deng; Jianguang Wang; Yanbin Chen; Like Zhang; Gangqiang Xie; Qipeng Liu; Ting Zhang; Pengfei Yuan; Dechun Liu
Journal:  Mol Med Rep       Date:  2016-06-14       Impact factor: 2.952

9.  CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.

Authors:  Wei Dai; Huilai Miao; Shuo Fang; Tao Fang; Nianping Chen; Mingyi Li
Journal:  Mol Med Rep       Date:  2016-06-17       Impact factor: 2.952

10.  ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1.

Authors:  Yang Zhou; Yunjiang Zhou; Keke Wang; Tao Li; Minda Zhang; Yunjia Yang; Rui Wang; Rong Hu
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.